Clinical trials: Depression Symptom
Depression
Japanese Phase 1 Multiple Ascending Dose (MAD) Study
The purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of BMS-820836 in healthy Japanese subjects and Japanese patients with depression.
- Trial name
- NCT01396252
- Testing
- BMS-820836
- Where
- Japan
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Airway Obstruction, Sedation Complication
Evaluation of Medical Device for Airway Patency During Sedation (SW01-2022)
The goal of this four-part preclinical [I-II] and clinical [III-IV] trial is to compare, with randomised crossover study design [I-IV], a new medical airway device with standard procedure (biteblock or no device) for upper airway…
- Conditions
- Airway Obstruction, Sedation Complication, Safety Issues, Patient Satisfaction
- Trial name
- NCT05708651
- Testing
- Investigational device [I-IV], Comparator [I-IV]
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Stairway Medical AB
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- VLZ-MD-01 (NCT01473381)
- Testing
- Vilazodone, Citalopram
- Where
- 54 sites in United States
- Volunteers
- 1,162 people
- Sponsor
- Forest Laboratories
Suicide, Suicidal
CAMPUS Expanded "Classification and Assessment of Mental Health Performance Using Semantics Expanded"
Open enrollment study to collect data for the optimization of machine learning models for use in an app for the early detection of mental health and suicidal risk.
- Conditions
- Suicide, Suicidal, Suicide, Attempted, Suicidal Ideation
- Trial name
- CAMPUS-E (NCT04493736)
- Testing
- MHSAFE app recording
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Clarigent Health
Anxiety, Fear
An Exploratory Investigation of a CBD Supplement's Impact on Sleep, Stress, and Focus
A high-quality broad-spectrum cannabidiol supplement with a bio-terpene complex will be administered once daily. It is hypothesized that this supplement will lead to improvements in sleep, focus, and stress.
- Conditions
- Anxiety, Fear, Stress, Low Mood
- Trial name
- NCT05518019
- Testing
- The Daily Supplement
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Prima CBD
Depression
Digital Therapeutic vs Educational App for Depression Among Adolescents
The primary aim of this study is to investigate the difference in depression symptoms at 4-weeks across two types of programs for addressing depressive symptoms, including Woebot (WB002) and Digital Education (ED002).
- Trial name
- NCT05486611
- Testing
- W-GenZD Mobile Application, Digital Education Application (W-EdZD)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Woebot Health
Major Depressive Disorder
Efficacy of Electronic Cognitive Behavioral Therapy Application to Treat Major Depressive Disorder
The primary objective of this study is to evaluate the safety and efficacy of an electronic cognitive behavioral therapy application (eCBT Mood) compared to a control group consisting of a mood monitoring handheld computer…
- Trial name
- NCT01752608
- Testing
- eCBT Mood
- Where
- 2 sites in United States
- Sponsor
- MindApps
Depression, Anxiety
Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety
A prospective, multi-center, randomized, subject and outcome evaluator blind , parallel-group study evaluating the effect of pharmacogenetic-guided versus standard of care treatment for subjects diagnosed with depression and/or…
- Trial name
- NCT02878928
- Testing
- IDgenetix Neuropsychiatric Test Panel
- Where
- 17 sites in United States
- Volunteers
- 579 people
- Sponsor
- AltheaDx
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an…
- Trial name
- SPARC-TMS (NCT07227103)
- Testing
- Neuronavigated robotic-enabled TMS, NRX-101
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- NeuroRx, Inc.
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder
- Trial name
- NCT01034462
- Testing
- Levomilnacipran ER
- Where
- 23 sites in United States
- Volunteers
- 442 people
- Sponsor
- Forest Laboratories
Skin Fold, Skin Laxity
A Safety and Effectiveness Study of CELLBOOSTER® Lift (Stabilized Booster Complex Using CHAC Technology)
The current post-market clinical investigation has been designed to evaluate the efficacy and safety of CELLBOOSTER® Lift, a HA-based product marketed by SUISSELLE SA.
- Conditions
- Skin Fold, Skin Laxity, Skin Texture Disorder, Skin Depression
- Trial name
- NCT06000839
- Testing
- (D0) Intradermal injection - micropapula technique, (D14) Intradermal injection - micropapula technique, (D28) Intradermal injection - micropapula technique
- Where
- France
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Suisselle
Major Depressive Disorder
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study
This study is an optional continuation of previous short-term adult major depressive disorder (MDD) augmentation studies. Patients may only take part in this long-term, open-label research study if they completed a previous…
- Trial name
- NCT01436175
- Testing
- SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
- Where
- 212 sites in United States, Canada and 12 more
- Volunteers
- 1,570 people
- Sponsor
- Shire
Depression
Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189
This is a subject single blinded, randomized, placebo-controlled, single dose, first-time-in-human study with three or more ascending cohorts.
- Trial name
- NCT01310881
- Testing
- NSI-189 Phosphate
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Neuralstem Inc.
Idiopathic Parkinson's Disease
Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients
The purpose of this study was to show superiority of Rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson's disease.
- Trial name
- NCT01523301
- Testing
- Rotigotine
- Where
- 29 sites in South Korea
- Volunteers
- 380 people
- Sponsor
- UCB Korea Co., Ltd.
Depression in Patients With Bipolar Disorder
Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression
This study will evaluate the efficacy and safety of different doses of Lu AA34893 in the treatment of depression in patients with bipolar disorder.
- Trial name
- NCT00622245
- Testing
- Lu AA34893, Quetiapine fumarate
- Where
- 50 sites in Australia, Austria and 16 more
- Volunteers
- 166 people
- Sponsor
- H. Lundbeck A/S
Depression, Cognition
Study of Duloxetine in Elderly Patients With Major Depressive Disorder
A study of the safety and efficacy of duloxetine in elderly patients (greater than 65 years old) with major depressive disorder
- Trial name
- NCT00062673
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 311 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive…
- Trial name
- NCT04513912
- Testing
- Seltorexant, Quetiapine XR
- Where
- 175 sites in United States, Argentina and 13 more
- Volunteers
- 757 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)
The study will assess efficacy, safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine in patients with Major Depressive Disorder.
- Trial name
- NCT01110902
- Testing
- Agomelatine (AGO178C)
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 589 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder, Depression
TC-5214 as add-on the Treatment of Major Depressive Disorder
This is a multi-center, double blind, randomized, placebo-controlled, parallel group, flexible dose titration study conducted in centers in the USA and India.
- Trial name
- NCT00692445
- Testing
- TC-5214 + citalopram
- Where
- 27 sites in United States, India
- Volunteers
- 574 people
- Sponsor
- Targacept Inc.